Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Norway
Management Report
Published: January 2010
Pages: 52
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
The population of Norway is estimated to be 4.9 million in 2010, with 15.0% of the total aged 65 years and over. Norway has a stable, affluent economy but has nevertheless been affected by the global economic downturn, with GDP contracting by 1.8% in 2009. However, Norway’s economy is expected to recover much sooner than other Nordic countries, with real GDP growth rising to 1.4% in 2010 and 2.0% in 2011, according to figures from the Economist Intelligence Unit. Meanwhile, healthcare expenditure has continued its steady growth in recent years.
Although Norway is outside of the EU, its regulatory environment is aligned to EU regulations and access to the market is, therefore, relatively uncomplicated. All of the major international pharmaceutical companies are represented in Norway. The leading national pharmaceutical companies in Norway focus on generic production. Biotech companies are emerging in increasing numbers, in particular in areas where Norway enjoys a competitive advantage, such as in the maritime and technical fields of industry. Due to the small scale of domestic production, any increases in demand are likely to be met by imports.
Since generic substitution was established in 2001, generic drugs have been able to gain an increasing share of the market, in terms of value and volume. In 2008, generics had a 51.0% share of sales and a 73.8% share of the market by volume.
Pharmaceutical costs have been reduced since the step-price model was introduced in 2005. In 2008, the system applied to a total of 42 substances.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.
Although Norway is outside of the EU, its regulatory environment is aligned to EU regulations and access to the market is, therefore, relatively uncomplicated. All of the major international pharmaceutical companies are represented in Norway. The leading national pharmaceutical companies in Norway focus on generic production. Biotech companies are emerging in increasing numbers, in particular in areas where Norway enjoys a competitive advantage, such as in the maritime and technical fields of industry. Due to the small scale of domestic production, any increases in demand are likely to be met by imports.
Since generic substitution was established in 2001, generic drugs have been able to gain an increasing share of the market, in terms of value and volume. In 2008, generics had a 51.0% share of sales and a 73.8% share of the market by volume.
Pharmaceutical costs have been reduced since the step-price model was introduced in 2005. In 2008, the system applied to a total of 42 substances.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.